Unknown

Dataset Information

0

Lower Urine Tenofovir Concentrations Among Individuals Taking Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate: Implications for Point-of-Care Testing.


ABSTRACT: From directly observed therapy studies, urine tenofovir (TFV) levels were 74% lower when taking tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate. Urine TFV remains quantifiable across a range of TAF adherence patterns, but a separate point-of-care lateral flow immunoassay with a lower TFV threshold will be needed to support TAF adherence monitoring.

SUBMITTER: Johnson KA 

PROVIDER: S-EPMC8286091 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC7096572 | biostudies-literature
| S-EPMC6954396 | biostudies-literature
| S-EPMC5264242 | biostudies-literature
| S-EPMC6905536 | biostudies-literature
| S-EPMC7935460 | biostudies-literature
| S-EPMC10776286 | biostudies-literature
| S-EPMC6763637 | biostudies-literature
| S-EPMC6635043 | biostudies-literature
| S-EPMC10906193 | biostudies-literature
| S-EPMC10863550 | biostudies-literature